U-LABA/ICS Effects on Exercise Performance, Vilanterol
ConditionExercise Performance
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-39
SponsorMorten Hostrup, PhD
About this trial
The purpose of the project is to investigate exercise performance in humans following bronchodilation induced by acute inhalation of beta2-agonist vilanterol + fluticasone furoate
Eligibility criteria
Qualifiers
Age 18-39
Physically active > 5 h weekly
Maximal oxygen consumption classified as high or very high
Disqualifiers
Diagnosed with severe asthma and been in treatment with long-acting beta2-agonist/corticosteroid
ECG abnormality
ACQ score > 1.5
Severe bronchial hyperreactivity as determined by mannitol test
Trial design
Treatments tested in this trial
- Vilanterol and Fluticasone Furoate (low dose)
- Vilanterol and Fluticasone Furoate (high dose)
- Placebo
Treatment groups
30 Participants
are divided into 2 treatment groupsSponsors and collaborators
Morten Hostrup, PhD
Lead sponsor
University of Copenhagen
Sponsor institution
Source ClinicalTrials.gov